Oncorus Equity Ratio

What does Oncorus do? Oncorus, Inc. develops viral immunotherapies through its self-amplifying RNA platform, with product candidates ONCR-021 and ONCR-788. ONCR-021, an IV-administered viral RNA encapsulated in lipid nanoparticles, targets non-small cell lung cancer, renal cell carcinoma, melanoma, anaplastic thyroid cancer, and hepatocellular carcinoma. ONCR-788 encodes a modified Seneca Valley Virus for cancer treatment. The company also works on its HSV platform, including ONCR-719, designed to enhance potency and anti-tumor immunity compared to prior viral immunotherapies. Oncorus generates revenue through research and development contracts and potential future product sales from its pipeline. Oncorus focuses on oncology segments, targeting multiple cancer types with its viral immunotherapy platform. The company's research and development efforts are directed at advancing ONCR-021, ONCR-788, and ONCR-719 for clinical development. As a biotechnology firm, Oncorus relies on partnerships and licensing agreements to fund its R&D activities, with potential future commercialization of its therapies in the oncology market. The company's product candidates are developed for specific cancer indications, with ONCR-021 targeting five distinct cancer types and ONCR-788 targeting tumors through a modified virus. ONCR-719 is part of the HSV platform, aiming to improve upon existing viral immunotherapy limitations. Oncorus' business model centers on advancing these therapies through clinical trials and eventual commercialization, with revenue streams expected from R&D contracts and product sales. Oncorus is one of the most popular companies on Eulerpool.